Stocks
Funds
Screener
Sectors
Watchlists
BLUE

BLUE - Bluebird Bio Inc Stock Price, Fair Value and News

$17.50-0.05 (-0.28%)
Market Closed

8/100

BLUE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

BLUE

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BLUE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLUE Price Action

Last 7 days

-0.6%

Last 30 days

-1.8%

BLUE RSI Chart

BLUE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BLUE Valuation

BLUE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BLUE Fundamentals

BLUE Revenue

BLUE Earnings

BLUE Profitability

BLUE Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.0M9.4M21.7M0
20224.7M6.1M5.1M3.6M
2021189.0M127.2M65.4M3.7M
202054.1M239.7M250.0M250.7M
201951.1M56.5M53.9M44.7M
201844.6M35.7M39.5M54.6M
201711.5M26.7M32.8M35.4M
20169.2M5.8M6.1M6.2M
201525.4M24.0M19.0M14.1M
201425.4M25.4M25.4M25.4M
20131.4M7.6M13.9M20.2M
20120274.7K307.3K340.0K
2011000242.0K
BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
 CEO
 WEBSITEbluebirdbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES323

Bluebird Bio Inc Frequently Asked Questions


BLUE is the stock ticker symbol of Bluebird Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.